Gruenenthal Gmbh

Grunenthal Gmbh

Johannes Schneider

Oswald K Zimmer

Stephan Wnendt

Klaus Schiene

Michael Haurand

Ulrich G Seipp

Werner Guenter Englberger

Derek John Saunders

Ulrich Jahnel

Werner P Vollenberg

Gerd J Steffens

Thomas Tzschentke

Kai Zwingenberger

Regina Heinzel-Wieland

Ilona Steigerwald

Michel Hamon

Bernd Sundermann

Gregor Bahrenberg

Hagen-Heinrich Hennies

Matthias Gerlach

Corinna Maul

Wolfgang Werner Strassburger

Georg Schramm

Silvia Reinartz

Werner Winter

Michael Finkam

Kurt Eger

Horst R Boehlke

Christa Kneip

Clemens Gillen

Bernd Zimmermann

Heide Hecker-Kia

Norbert Ulbrich

Michaela Akermann

Brigitte J Bosman

The use of tapentadol in the treatment of pain and/or pain chronification in a subject suffering from pain chronification and/or in the treatment of pain and inhibition of pain chronification in a subject suffering from pain and at risk of pain chronification, as well as the use of tapentadol for the treatment or inhibition of migraine.

Method of inhibiting chronification of pain

The present invention relates to substituted cyclopentene compounds of the general formula I, to a process for the production thereof, to pharmaceutical preparations containing these compounds and to the use thereof for the production of pharmaceutical preparations.

Substituted cyclopentene compounds

Tert -butyl-(7-methyl-imidazol &lsqb;1,2-a&rsqb;pyridin-3-yl)-amine derivatives

Use of catechol derivatives as proteinase inhibitors

Lactam derivatives as immunomodulating agents

Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action

Bifunctional urokinase variants possessing improved fibrinolytic properties and thrombin inhibitory activities, plasmids used in the production of these polypeptides, as well as thrombolytic agents containing one of the bifunctional urokinase variants as active ingredient are described.

Bifunctional urokinase variants with improved fibrinolytic

Substituted 3,4-dihydronaphthalenes of the formula I ##STR1## wherein R.sup.1 is a methyl or an amino group, R.sup.2 represents a hydrogen atom or a methyl group, and R.sup.3 is a linear or branched chain alkyl residue having 1 to 4 carbon atoms, an allyl or a crotyl group or a cyclopentyl group are disclosed which specifically inhibit 5-lipoxygenase and are useful in pharmaceutical compositions for prophylaxis and treatment of disorders attributable to the action of leucotrienes. The dihydronaphthalenes may be prepared by reacting a compound of formula II ##STR2## with hydroxylamine or a salt thereof to form the corresponding oxime, reducing the oxime to a hydroxylamine of formula III ##STR3## and introducing a --CO--R.sup.1 group.

Substituted 3,4-dihydronaphthalenes, pharmaceutical compositions

An acetohydroxamic acid compound of formula I ##STR1## as such or in form of a complex with .beta.-cyclodextrin or hydroxypropyl-.beta.-cyclodextrin specifically inhibits 5-lipoxygenase and is useful in pharmaceutical compositions for prophylaxis and treatment of diseases due to the action of leucotrienes. The acetohydroxamic acid compound may be prepared by reacting 3-thiophenecarboxaldehyde with hydroxylamine or a salt thereof to form the corresponding oxime, reducing the oxime with a boron-containing reducing agent to form N-(thien-3-yl)methyl-hydroxylamine, and introducing an acetyl group.

Acetohydroxamic compound and complexes pharmaceutical compositions

Substituted phenylacetylenes of the formula ##STR1## wherein one of the groups R.sub.1 is a hydrogen atom and the other represents the group of the formula ##STR2## in which R.sub.3 is hydrogen, methyl or ethyl and R.sub.4 is a methyl or an amino group and wherein R.sub.2 represents mono- or binuclear aromatic or heterocyclic residues containing sulfur, nitrogen or oxygen as hetero atoms and optionally being substituted by 1 to 3 substituents as defined, which specifically inhibit 5-lipoxygenase and are useful in pharmaceutical compositions for prophylaxis and treatment of diseases due to the action of leukotrienes. The compounds may be prepared by reacting a compound of the formula ##STR3## wherein R.sub.2 has the same meaning as above and one of the groups R.sub.7 is a hydrogen atom and the other represents the group of the formula --COR.sub.3, with hydroxylamine to form the oxime which then is reduced to the corresponding hydroxylamine compound into which the group of the formula --COR.sub.4 is introduced.

Substituted phenylacetylenes, pharmaceutical compositions containing

Growing community of inventors

Stolberg, Germany

Johannes Schneider